Growth factor receptor-mediated mitogenic signaling pathway (None)

The "growth factor receptor-mediated mitogenic signaling pathway" refers broadly to cellular signal transduction cascades initiated by binding of extracellular growth factors—such as EGF, FGF, PDGF—to their respective cell surface receptors. These receptors are typically transmembrane proteins with intrinsic enzymatic activity—most commonly receptor tyrosine kinases, which dimerize upon ligand binding and autophosphorylate key residues on their cytoplasmic domains. This phosphorylation recruits adaptor proteins that activate intracellular cascades including the Ras/Raf/MEK/ERK (MAP kinase) and PI3K/Akt pathways. These signals ultimately regulate gene expression programs controlling cell proliferation ("mitogenesis"), survival, differentiation, migration and tissue homeostasis.[1][2][3][4] Dysregulation—by overexpression or mutation—of these pathways is implicated in cancer development and other diseases.[2][4] While many drugs have been developed against individual components such as EGFR or FGFRs,[2] "growth factor receptor-mediated mitogenic signaling" itself is not considered a single druggable entity but rather encompasses multiple targets within its network. In summary: The provided name does not correspond to an individual molecular target but instead describes an entire family of related signal transduction processes involving various growth factors and their membrane-bound receptors.[1][3] For structured data purposes it should be flagged as incorrect/non-canonical for use as a therapeutic target entry.

Other names

Growth factor signaling pathwayMitogenic growth factor signalingReceptor tyrosine kinase (RTK) mitogenic pathways

Not applicable directly to the pathway as a whole; mechanisms of action for drugs targeting components of this pathway include inhibition of ligand binding to receptors (e.g., monoclonal antibodies against EGFR) and inhibition of kinase activity in RTKs or downstream effectors like MEK/ERK.